Management of Behavioral Aggressiveness in Vascular Dementia

Guideline-Recommended Treatment Hierarchy

The Canadian Stroke Best Practice Recommendations suggest that trazodone should not be used as first-line treatment for behavioral aggressiveness in vascular dementia; SSRIs are the preferred pharmacological option 1, 2, 3, 4
Non-pharmacological approaches, including simulated presence therapy, massage therapy, animal-assisted interventions, and personally tailored behavioral interventions, must be attempted first 1, 2, 3, 4
Physical activity programs should be implemented as they reduce behavioral symptoms in vascular cognitive impairment 1, 2, 3, 4
SSRIs are explicitly designated as first-line pharmacological treatments for agitation in vascular dementia 1, 2, 3, 4
Serotonergic antidepressants significantly improved overall neuropsychiatric symptoms, agitation, and depression in individuals with vascular cognitive impairment 1, 2, 3, 4
SSRIs as a class significantly reduced overall neuropsychiatric symptoms, while non-SSRIs (which includes trazodone) did not demonstrate this benefit 1, 2, 3, 4
Both SSRIs and non-SSRIs reduced agitation, but SSRIs had broader neuropsychiatric benefits 1, 2, 3, 4

The WHO guidelines specifically state that trazodone should not be used for treatment of behavioral and psychological symptoms of dementia 6
Significant risks associated with trazodone include priapism, orthostatic hypotension, and cardiac arrhythmias, particularly concerning in elderly patients with vascular disease 7
The American Geriatrics Society notes these cardiovascular risks are particularly problematic in the geriatric population 7

Antipsychotics should be avoided or used with extreme caution due to increased mortality risk from cardiac toxicities in vascular dementia 1, 2, 3, 4
Reserve antipsychotics for severe agitation with imminent risk of harm when behavioral interventions and SSRIs have failed 5

Quantify baseline severity using Cohen-Mansfield Agitation Inventory or Neuropsychiatric Inventory Questionnaire 5
Reassess response after 4 weeks of adequate SSRI dosing 5
If no clinically significant response, taper and withdraw 5
Even with positive response, periodically reassess need for continued medication 5